Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2016

01-03-2016 | Bone and Soft Tissue Sarcomas

Prognosis of Primary and Recurrent Chondrosarcoma of the Rib

Authors: Eva Roos, MD, Frits van Coevorden, MD, PhD, Cornelis Verhoef, MD, PhD, Michel W. Wouters, MD, PhD, Herman M. Kroon, MD, PhD, Pancras C. W. Hogendoorn, MD, PhD, Winan J. van Houdt, MD, PhD, MSc

Published in: Annals of Surgical Oncology | Issue 3/2016

Login to get access

Abstract

Background

Chondrosarcoma of the rib is a rare disease. Although surgery is the only curative treatment option, rib resection with an adequate margin can be challenging and local recurrence is a frequent problem. In this study, the prognosis of primary and recurrent chondrosarcoma of the rib is reported.

Methods

Retrospective analysis was performed of patients treated for chondrosarcoma of the rib between 1984 and 2014 in three major tertiary referral centers in The Netherlands. Clinical and histopathological features were analyzed for their prognostic value using Kaplan–Meier and Cox proportional hazard analysis. Endpoints were set at local recurrent disease, metastasis rate, or death.

Results

Overall, 76 patients underwent a resection for a primary chondrosarcoma, and 26 patients underwent a resection for a recurrent chondrosarcoma. Five-year overall survival in the primary group was 90 %, local recurrence rate was 17 %, and metastasis rate was 12 %. The 5-year outcome after recurrent chondrosarcoma was lower, with an overall survival of 65 %, local recurrence rate of 27 %, and metastasis rate of 27 %. For primary chondrosarcoma, tumor size >5 cm and a positive resection margin were correlated with worse overall survival [hazard ratio (HR) 3.28, 95 % confidence interval (CI) 1.03–10.44; HR 2.92, 95 % CI 1.03–8.25). A higher histological grade was correlated with a higher local recurrence and metastasis rate (HR 5.92, 95 % CI 1.11–31.65; HR 6.96, 95 % CI 1.15–42.60).

Conclusion

Surgical resection of both primary and recurrent chondrosarcoma of the rib is an effective treatment strategy. The oncological outcome after surgery is worse in tumors >5 cm, in tumors with positive resection margins and grade 3 chondrosarcoma.
Literature
1.
Jeon DG, Song WS, Kong CB, Kim JR, Lee SY. MFH of bone and osteosarcoma show similar survival and chemosensitivity. Clin Orthop Relat Res. 2011;469(2):584–90.PubMedCentralCrossRefPubMed
2.
Bergovec M, Kubat O, Smerdelj M, Seiwerth S, Bonevski A, Orlic D. Epidemiology of musculoskeletal tumors in a national referral orthopedic department. A study of 3482 cases. Cancer Epidemiol. 2015;39(3):298–302.CrossRefPubMed
3.
Riedel RF, Larrier N, Dodd L, Kirsch D, Martinez S, Brigman BE. The clinical management of chondrosarcoma. Curr Treat Options Oncol. 2009;10(1–2):94–106.CrossRefPubMed
4.
Doyle LA. Sarcoma classification: an update based on the 2013 World Health Organization classification of tumors of soft tissue and bone. Cancer. 2014;120(12):1763–74.CrossRefPubMed
5.
Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. 1980. Clin Orthop Relat Res. 2003;415:4–18.CrossRefPubMed
6.
Eefting D, Schrage YM, Geirnaerdt MJ, Le Cessie S, Taminiau AH, Bovee JV, et al. Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. Am J Surg Pathol. 2009;33(1):50–7.CrossRefPubMed
7.
Schrage YM, Briaire-de Bruijn IH, de Miranda NF, van Oosterwijk J, Taminiau AH, van Wezel T, et al. Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res. 2009;69(15):6216–22.CrossRefPubMed
8.
Verdegaal SH, Brouwers HF, van Zwet EW, Hogendoorn PC, Taminiau AH. Low-grade chondrosarcoma of long bones treated with intralesional curettage followed by application of phenol, ethanol, and bone-grafting. J Bone Joint Surg Am. 2012;94(13):1201–7.CrossRefPubMed
9.
Fiorenza F, Abudu A, Grimer RJ, Carter SR, Tillman RM, Ayoub K, et al. Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg Br. 2002;84(1):93–9.CrossRefPubMed
10.
van Geel AN, Wouters MW, Lans TE, Schmitz PI, Verhoef C. Chest wall resection for adult soft tissue sarcomas and chondrosarcomas: analysis of prognostic factors. World J Surg. 2011;35(1):63–9.PubMedCentralCrossRefPubMed
11.
Wouters MW, van Geel AN, Nieuwenhuis L, van Tinteren H, Verhoef C, van Coevorden F, et al. Outcome after surgical resections of recurrent chest wall sarcomas. J Clin Oncol. 2008;26(31):5113–8.CrossRefPubMed
12.
Widhe B, Bauer HC. Surgical treatment is decisive for outcome in chondrosarcoma of the chest wall: a population-based Scandinavian Sarcoma Group study of 106 patients. J Thorac Cardiovasc Surg. 2009;137(3):610–4.CrossRefPubMed
13.
14.
Widhe B, Bauer HC. Diagnostic difficulties and delays with chest wall chondrosarcoma: a Swedish population based Scandinavian Sarcoma Group study of 106 patients. Acta Oncol. 2011;50(3):435–40.CrossRefPubMed
15.
Briccoli A, De Paolis M, Campanacci L, Mercuri M, Bertoni F, Lari S, et al. Chondrosarcoma of the chest wall: a clinical analysis. Surg Today. 2002;32(4):291–6.CrossRefPubMed
16.
Sabanathan S, Shah R, Mearns AJ. Surgical treatment of primary malignant chest wall tumours. Eur J Cardiothorac Surg. 1997;11(6):1011–6.CrossRefPubMed
17.
Lin PP, Alfawareh MD, Takeuchi A, Moon BS, Lewis VO. Sixty percent 10-year survival of patients with chondrosarcoma after local recurrence. Clin Orthop Relat Res. 2012;470(3):670–6.PubMedCentralCrossRefPubMed
18.
Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer. 1977;40(2):818–31.CrossRefPubMed
19.
Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R, Scully SP. Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am. 2009;91(5):1063–72.CrossRefPubMed
20.
Lee FY, Mankin HJ, Fondren G, Gebhardt MC, Springfield DS, Rosenberg AE, et al. Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am. 1999;81(3):326–38.PubMed
21.
Aarons C, Potter BK, Adams SC, Pitcher JD Jr, Temple HT. Extended intralesional treatment versus resection of low-grade chondrosarcomas. Clin Orthop Relat Res 2009;467(8):2105–11.PubMedCentralCrossRefPubMed
22.
23.
Fong YC, Pairolero PC, Sim FH, Cha SS, Blanchard CL, Scully SP. Chondrosarcoma of the chest wall: a retrospective clinical analysis. Clin Orthop Relat Res. 2004(427):184–9.CrossRefPubMed
24.
Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS. Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57(3):739–47.CrossRefPubMed
25.
Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer. 2003;97(10):2530–43.CrossRefPubMed
26.
van Houdt WJ, Westerveld CM, Vrijenhoek JE, van Gorp J, van Coevorden F, Verhoef C, et al. Prognosis of solitary fibrous tumors: a multicenter study. Ann Surg Oncol. 2013;20(13):4090–5.CrossRefPubMed
Metadata
Title
Prognosis of Primary and Recurrent Chondrosarcoma of the Rib
Authors
Eva Roos, MD
Frits van Coevorden, MD, PhD
Cornelis Verhoef, MD, PhD
Michel W. Wouters, MD, PhD
Herman M. Kroon, MD, PhD
Pancras C. W. Hogendoorn, MD, PhD
Winan J. van Houdt, MD, PhD, MSc
Publication date
01-03-2016
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 3/2016
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-4932-2

Other articles of this Issue 3/2016

Annals of Surgical Oncology 3/2016 Go to the issue

Breast Oncology

Occult Histopathology and Its Predictors in Contralateral and Bilateral Prophylactic Mastectomies

Bone and Soft Tissue Sarcomas

Complications and Postoperative Mortality Rate After Surgery for Pathological Femur Fracture Related to Bone Metastasis: Analysis of a Nationwide Database

Colorectal Cancer

Mutation Spectra of Common Cancer-Associated Genes in Different Phenotypes of Colorectal Carcinoma Without Distant Metastasis

Reconstructive Oncology

Optimization of Free-Flap Limb Salvage and Maximizing Function and Quality of Life Following Oncologic Resection: 12-Year Experience

Colorectal Cancer

Survival Benefit of Exercise Differs by Tumor IRS1 Expression Status in Colorectal Cancer

Editorial

Lobular Neoplasia: Another Reset in Management?